#Ireland #Dublin #Theravance Biopharma #Ampreloxetine #Neurogenic Orthostatic

Theravance Biopharma Showcases Ampreloxetine Research at AAN 2025

Theravance Biopharma, a biotechnology company based in Dublin, made significant strides in the ongoing search for effective treatments for neurogenic orthostatic hypotension (nOH), a condition that affects many patients with progressive neurodegenerative diseases. During the Annual Meeting of the American Academy of Neurology (AAN) held from April 5 to April 9, 2025, in San Diego, two compelling analyses of their investigational drug, ampreloxetine, were presented, highlighting the drug's potential in alleviating symptoms associated with this debilitating condition.

The Need for Effective nOH Treatments

Neurogenic orthostatic hypotension is characterized by a substantial drop in blood pressure upon standing, resulting in symptoms such as dizziness, fainting, and fatigue. It is particularly prevalent in patients suffering from multiple system atrophy (MSA) and Parkinson's disease. Despite the available treatments existing in the market, many patients experience inadequate relief, often resorting to multiple antihypotensive agents without satisfactory results. Therefore, the introduction of new therapies—such as ampreloxetine—offering a unique mechanism of action and improved safety profiles is of paramount importance.

Insights from the Phase 3 Analyses

The Phase 3 program of ampreloxetine, a selective norepinephrine reuptake inhibitor, included two pivotal clinical trials that enabled researchers to explore its efficacy in treating symptomatic nOH.

1. Study 0169: This trial demonstrated that participants treated with ampreloxetine showed a significant mean increase of 58% in venous plasma norepinephrine levels after four weeks, benefiting most notably patients with MSA, who exhibited a 79% increase.
2. Study 0170: Following a 16-week open-label phase, it was observed that the target engagement continued even after treatment was paused, leading to a sustained improvement in blood pressure regulation among patients that had experienced active treatment.

These studies were instrumental in reinforcing the drug's targeted mechanism, evidencing the capacity of ampreloxetine to effectively inhibit norepinephrine reuptake while ensuring the safety of patients by not exacerbating supine hypertension—an important consideration given that patients often struggle with elevated blood pressure while lying down.

Worrisome Side Effects Addressed

The inherent challenge of treating nOH lies in the risk of aggravating other conditions like supine hypertension with existing therapies. Previous FDA-approved medications typically come with black-box warnings due to this risk. Researchers at Theravance Biopharma were encouraged by findings from Study 0169, as patients on ampreloxetine did not exhibit significant worsening of their supine hypertension as monitored both in-clinic and through ambulatory blood pressure assessments conducted over several days.

Expert Insights

Dr. Valeria Iodice, an honorary associate professor of neurology who presented the analyses at AAN, remarked, “nOH represents a persistent unmet need; effective long-term treatments are crucial. With this data, we see the promise ampreloxetine holds in uniquely targeting symptoms of nOH while mitigating risks associated with traditional therapies.”

Moreover, Dr. Lucy Norcliffe-Kaufmann highlighted that the innovative mechanism of action employed by ampreloxetine could offer significant relief without the complications of surgery or drastic lifestyle changes usually warranted for managing high blood pressure.

Looking Ahead: The Future of Ampreloxetine

In light of these findings, Theravance Biopharma plans to push the boundaries of their research on ampreloxetine further. Currently, the company is conducting a registrational Phase 3 study titled CYPRESS, which aims to solidify its efficacy through rigorous testing. If successful, Theravance could file an application for the drug's approval, potentially changing the landscape of treatment for those with symptomatic nOH associated with multiple system atrophy and similar disorders.

As Theravance Biopharma continues its exploration into the capabilities of ampreloxetine, there remains a palpable sense of hope within the neurology community. With potentially effective treatment options on the horizon, patience for those suffering the debilitating effects of neurogenic orthostatic hypotension may finally find the long-awaited relief they so greatly deserve.